Ono Takashi, Yamamoto Naoyoshi, Nomoto Akihiro, Nakajima Mio, Isozaki Yuka, Kasuya Goro, Ishikawa Hitoshi, Nemoto Kenji, Tsuji Hiroshi
Department of Radiation Oncology, QST Hospital, 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan.
Department of Radiation Oncology, Faculty of Medicine, Yamagata University, 2-2-2, Iida-Nishi, Yamagata 990-9585, Japan.
Cancers (Basel). 2020 Dec 31;13(1):112. doi: 10.3390/cancers13010112.
The purpose of the present study was to evaluate the efficacy and safety of single-fraction carbon-ion radiotherapy (CIRT) in patients with non-small cell lung cancer.
Patients with histologically confirmed non-small cell lung cancer, stage T1-2N0M0, and treated with single-fraction CIRT (50Gy (relative biological effectiveness)) between June 2011 and April 2016 were identified in our database and retrospectively analyzed. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events version 4.0.
The study included 57 patients, 22 (38.6%) of whom had inoperable cancer. The median age was 75 years (range: 42-94 years), and the median follow-up time was 61 months (range: 6-97 months). The 3- and 5-year overall survival rates were 91.2% and 81.7%, respectively. All survivors were followed up for more than three years. The 3- and 5-year local control rates were 96.4% and 91.8%, respectively. No case of ≥ grade 2 pneumonitis was recorded.
This study suggests that single-fraction CIRT for T1-2N0M0 non-small cell lung cancer patients is feasible and can be considered as one of the treatment choices, especially in medically inoperable patients.
本研究的目的是评估单次分割碳离子放疗（CIRT）治疗非小细胞肺癌患者的疗效和安全性。
在我们的数据库中识别出2011年6月至2016年4月期间接受单次分割CIRT（50Gy（相对生物效应））治疗的组织学确诊为非小细胞肺癌、T1-2N0M0期的患者，并进行回顾性分析。使用不良事件通用术语标准第4.0版评估毒性。
该研究纳入了57例患者，其中22例（38.6%）患有无法手术的癌症。中位年龄为75岁（范围：42-94岁），中位随访时间为61个月（范围：6-97个月）。3年和5年总生存率分别为91.2%和81.7%。所有幸存者均随访超过三年。3年和5年局部控制率分别为96.4%和91.8%。未记录到≥2级肺炎病例。
本研究表明，单次分割CIRT治疗T1-2N0M0非小细胞肺癌患者是可行的，可被视为治疗选择之一，尤其是对于医学上无法手术的患者。
